Eupraxia Pharmaceuticals (EPRX) Revenue (2023 - 2025)

Eupraxia Pharmaceuticals' (EPRX) quarterly Revenue came in at $359739.0 in Q1 2025, down 58.3% year-on-year from $862683.0 in Q1 2024, and down 58.3% on a QoQ basis from $862683.0 in Q1 2024.

Eupraxia Pharmaceuticals (EPRX) Revenue (2023 - 2025) Analysis & Trends

Eupraxia Pharmaceuticals (EPRX) has 3 years of Revenue data on file, last reported at $359739.0 in Q1 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Revenue (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn - -
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn 1.51 Bn
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn 2.99 Bn
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn 3.61 Bn
7 Belite Bio 61.40 Bn 61.40 Bn - -
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn 1.30 Bn
9 Revolution Medicines 37.37 Bn 37.37 Bn - -
10 Eupraxia Pharmaceuticals 329.50 Mn 329.50 Mn - -

Historic Data

Download Data
DateValue
Mar 31, 2025 359,739.00
Mar 31, 2024 862,683.00
Mar 31, 2023 -128,152.00